Manage Your Liver
Q:

NAFLD could lead to injury in other organs

NAFLD could lead to injury in other organs
A:

Nonalcoholic fatty liver disease (NAFLD) is a condition in which fat builds up in your liver. NAFLD is one of the most common causes of liver disease in the United States. Between 30 and 40 percent of adults in the United States have NAFLD. About 3 to 12 percent of adults in the United States have NASH (a form of NAFLD in which you have inflammation and liver cell damage). [1]

Recent research found that NAFLD not only increases the risk of chronic liver diseases such as NASH, liver cirrhosis and liver cancer but also the risks for type 2 diabetes, cardiovascular diseases and more. 


Scientists at the University of Tübingen found the cause for this is the altered secretion behaviour of the fatty liver. It increasingly produces glucose, and unfavourable fats and protein called hepatocyte fetuin-A, all of which it releases into the bloodstream. They also found that treating pancreatic fat cells with fetuin-A led to increased inflammation and a greater threat from immune cells, and could damage kidney function.

While having some fat contained in the liver is not harmful, it could turn into NAFLD, NASH and other types of chronic liver problem and the protein that fatty liver produces could also cause damages to other organs including pancreas and kidney.

Study author Professor Hans-Ulrich Häring said it was the effect of the fetuin-A protein that led to "pathological changes", including a restricting of kidney function. While fat tissue is not harmful in some parts of the body, within the liver, fat tissue becomes dangerous and produces fetuin-A, which elicits inflammatory processes.

Disclaimer:
  • * All research and clinical data should be used as reference purposes only, results may vary.
Related Questions
A:
“It isn't fat but rather fibrosis that drives disease progression in people with advanced non-alcoholic steatohepatitis (NASH).”   NASH is one of the most prevalent liver diseases nowadays. NASH is related to non-alcoholic fatty liver disease (NAFLD) which is characterized by the buildup of fat in the liver. Although it is normal to have some fat in the liver, some people might develop inflammation because of this fat accumulation, this is cal
A:
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are common liver diseases. They occur in people who drink little or no alcohol at all and are considered to be consequences of obesity.    However, “not obese” does not equal “no NAFLD / NASH”, since NAFLD may not be linked with obesity in some cases. Fatty liver disease may also develop in non-obese people. The terms “lean NAFLD” and “lean
Hit Questions
A:
Fibrosis is scarring of the liver that results from chronic inflammation. It is a process where the damaged, dying liver cells are replaced by fibrous scar tissue, causing the liver to become hard. The extent of liver fibrosis can vary, and it is often classified in several stages. The most common classification is a scale from F0 to F4. F0 indicates no fibrosis. A normal liver is at a stage between F0 and F1. F2 denotes light fibrosis, and F3 indicates severe fibrosis. When scar tissue build
A:
You probably have already heard about the new antiviral hep C drug, which is effective but insanely expensive. It claims to have around 90% success rate, that’s why so many hepatitis C patients are dying for it even though it’s extremely costly. But apart from its expensive price tag, there is a bigger issue behind this new drug that not many people know about. Scientists and researchers have found an increased risk of extreme liver cancer related to this new drug after successful
A:
ALT (Alanine Aminotransferase / SGPT) is an enzyme that is mainly found in liver cells. The level of ALT in our bloodstream is the primary indicator of liver health.   What does high ALT indicate? ALT enzymes are normally contained within liver cells when the liver is healthy, but when the liver cells are injured or damaged by whatever means, ALT enzymes are released into the bloodstream, causing levels to go up. Therefore, by measuring the
A:
Hepatitis C is a wide spread and deadly disease affecting an estimated of 3.5 million Americans.   Treatment for hepatitis C has evolved over the years, going from highly toxic drugs involving injections with horrible side effects, to medications with minimal side effects. Success rate of treatment options has also improved greatly Although the high price tag of the new DAA treatment is controversial, it has undoubtedly helped to cure many hepatitis C patients.
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Have Questions?
Sumbit your question to us for profeessional answers!
Looking for help? Ask our customer support team!
Contact Us